ClinicalTrials.gg
RecruitingNCT06731049Updated Mar 31, 2026

Comparison of the Effectiveness of Treadmill-Based Walking and Dual-Task Walking Training in Alzheimer's Disease

An interventional study of Treadmill-based Training Group and Dual-Task Treadmill-based Training Group in Alzheimer' Disease and Dementia, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Primary conditionDementiaRegistry: DiseaseReclassifiedWhy we changed it
Registry
Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dementia
Why
  1. Disease describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Dementia with a site in Turkey — 6 open to participants now, 10 under way, none of them phase 3. Dementia · Turkey.

Planned enrollment
21st of 32
46 · median 56
Started
2025
with 4 others
No phase
29 of 40
2 open now
Registered
26th of 40
by date
Lead sponsor
4 of 40
Istanbul University - Cerrahpasa

Among the 40 studies in Dementia with a site in Turkey, this one is the 21st largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2025, is one of 29 with no phase, and was the 26th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

6 of the 40 studies in Dementia with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Dementia with a site in Turkey, or all of them as a file.
02

Study summary

Alzheimer's disease is a neurodegenerative condition that affects both cognitive and motor functions, making daily life activities more challenging. Motor functions, especially walking and balance, begin to deteriorate early in the disease and progress in parallel with cognitive decline. Dual-task performance, which refers to the ability to perform both motor and cognitive tasks simultaneously, significantly decreases in individuals with Alzheimer's disease. Current studies suggest that dual-task exercises can improve both cognitive and motor functions. In this context, treadmill-based dual-task training emerges as a promising approach to mitigate the effects of Alzheimer's disease. The study hypothesizes that treadmill-based dual-task training will have more positive effects on motor and cognitive parameters compared to treadmill exercise alone in individuals with Alzheimer's disease. The main research question of this study is whether treadmill-based dual-task exercise training, designed with progressively more challenging cognitive and motor tasks and tailored to the individual, results in significant improvements in motor and cognitive parameters, as well as daily living activities and dual-task performance, compared to a group that only undergoes treadmill exercise.

Read the detailed description

The aim of this project is to investigate the effects of treadmill-based dual-task exercise training, which is individually designed and progressively challenging, on functional mobility, cognitive function, walking speed, balance, and dual-task performance in Alzheimer's disease. The results obtained from this training will be compared only to those of treadmill-based walking training. The goal of this project is to enhance the level of independence in daily life by improving cognitive and physical parameters related to body structure and function. In the study, for 8 weeks, the Treadmill-based Training Group will receive walking training on the treadmill twice a week, while the Dual-Task Treadmill-based Training Group will undergo dual-task walking training, which includes both motor and cognitive tasks on the treadmill. At the beginning and end of the 8-week training period, functional mobility, cognitive function, ability to perform activities of daily living, balance, walking speed, and dual-task performance will be measured.

03

Conditions studied

  • Alzheimer' Disease
  • Dementia

Browse trials for

Keywords

  • Treadmill
  • Dual-task
  • Exercise
  • Rehabilitation
  • Physiotherapy and rehabilitation
04

In context

Dementia Reclassified

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

This study's planned enrollment of 46 is below the median of 90 across 1,761 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.

Compared within Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Alzheimer's disease according to the NINCDS-ADRDA criteria by a neurologist,
  2. In the early or middle stages of the disease according to the Clinical Dementia Rating Scale (CDR),
  3. Receiving medical treatment for Alzheimer's disease (e.g., cholinesterase inhibitors or memantine) for at least the past month,
  4. Able to walk at least 400 meters in the 6-Minute Walk Test, indicating functional mobility,
  5. Able to read and understand instructions given in Turkish.

Exclusion criteria

Exclusion Criteria:

  1. Having Lewy body dementia, frontotemporal dementia, or other types of dementia
  2. Participating in a structured exercise program within the 6 months prior to starting the study
  3. Having pulmonary, neurological, musculoskeletal, or rheumatological diseases that hinder walking
  4. Having an unstable medical condition (e.g., uncontrolled diabetes or hypertension, deep vein thrombosis, etc.)
  5. Having visual or auditory impairments that make communication difficult
  6. Having behavioral problems that make participation in exercise difficult
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Active comparator
    Treadmill Based Training Group

    In the study, for 8 weeks, the Treadmill-based Training Group will undergo walking training on a treadmill two days a week.

  • Experimental
    Dual-Task Treadmill Based Training Group

    Dual-Task Treadmill-based Training Group will receive dual-task walking training involving both motor and cognitive tasks on the treadmill for 8 week, two days in a week.

Interventions

  • OtherTreadmill-based Training Group

    The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.

  • OtherDual-Task Treadmill-based Training Group

    In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.

07

What researchers measure

Primary outcomes

  1. Timed Up and Go Test

    Timed Up and Go Test (TUG) In the Timed Up and Go Test, the participant is instructed to stand up from a fixed chair placed on a non-slip surface with their knees and hips at approximately 90 degrees, walk 3 meters, turn around, and sit back down. The time taken to complete these activities is recorded.

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Trail Making Test

    The Trail Making Test, used to assess executive functions, has two versions: A and B. In version A, a page with scattered numbers is given to the participant, and they are asked to connect the numbers from 1 to 25 in sequence as quickly as possible. In version B, a page with both numbers (1-13) and letters (A-L) is provided. The participant is instructed to connect the numbers and letters in sequence, alternating between 1-A-2-B-3-C, and so on. The time taken to complete each task is recorded in seconds.

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

    The ADCS-ADL, developed specifically for Alzheimer's disease, consists of 23 items-6 basic and 17 instrumental activities of daily living-that assess the participant's level of independence. Questions are directed to the caregiver, focusing on the participant's performance over the last 4 weeks. The total score ranges from 0 to 78, with lower scores indicating higher levels of dependency.

    Time frame: From enrollment to the end of treatment at 8 weeks

Secondary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    MoCA is a widely used screening test for global cognitive function. It assesses cognitive abilities in 6 domains: calculation, abstract thinking, orientation, executive function, memory, verbal fluency, attention, and visual-spatial abilities. A total score above 21 indicates normal cognitive function.

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Verbal Fluency Test

    The Verbal Fluency Test evaluates verbal fluency and executive functions under two categories: phonemic and semantic fluency. In the phonemic fluency section, the number of words starting with the letters K, A, and S produced by the participant is recorded. In the semantic fluency section, the total number of words related to selected categories such as animals, fruits, furniture, or vehicles is recorded. The total time for the test is 60 seconds, and the number of words produced every 15 seconds is recorded separately.

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Digit Span Test

    This test is used to assess short-term memory and attention. In the forward digit span section, the participant is asked to repeat the numbers read aloud by the examiner in the same order, while in the backward digit span section, they must repeat the numbers in reverse order. The test begins with a span of 3 numbers, and after correctly repeating the given sequence, the length of the number sequence is increased one digit at a time (e.g., 3-7, 1-5-9, 4-8-2-7, 6-3-1-9-2).

    Time frame: From enrollment to the end of treatment at 8 weeks

  4. Four-Step Balance Test

    This test is used to measure static balance. The participant is asked to stand for 10 seconds in four different positions on a firm and stable surface: with both feet together, semi-tandem, tandem, and one foot.

    Time frame: From enrollment to the end of treatment at 8 weeks

  5. 10-Meter Walk Test

    The 10-Meter Walk Test is a performance-based test used to evaluate walking speed. A 14-meter distance is measured, with an additional 2 meters at the start and end of the walking path. The time taken to walk the 10-meter distance is recorded in seconds.

    Time frame: From enrollment to the end of treatment at 8 weeks

  6. Dual-Task Performance

    Dual-task performance will be assessed by applying the Timed Up and Go Test along with cognitive tasks such as naming animals, generating words starting with the same letter, and repeating given sequences of numbers in order.

    Time frame: From enrollment to the end of treatment at 8 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 28 months is above that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Aug 1, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06731049
Responsible party
Kübra Nur Menengiç (Principal Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Dec 12, 2024
Start date
Aug 1, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Kübra Nur Menengiç, MSc
Contact
kmenengic@gmail.com
+90 216 547 26 00 ext. 2755
İpek Yeldan, Prof. Dr.
Contact
ipekyeldan@gmail.com
+90 212 866 37 00 ext. 28005

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion